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The prevalence of diabetes mellitus is increasing at a 
dramatic rate, and countries in Asia, particularly India 
and China, will bear the brunt of this epidemic. Persons 
with diabetes have a significantly increased risk of active 
tuberculosis (TB), which is two to three times higher 
than in persons without diabetes. In this article, we argue 
that the epidemiological interactions and the effects on 
clinical presentation and treatment resulting from the 
interaction between diabetes and TB are similar to those 
observed for human immunodeficiency virus (HIV) and 
TB. The lessons learned from approaches to reduce the 
dual burden of HIV and TB, and especially the modes of 
screening for the two diseases, can be adapted and ap-
plied to the screening, diagnosis, treatment and preven-
tion of diabetes and TB. The new World Health Organi-
zation (WHO) and The Union Collaborative Framework 
for care and control of TB and diabetes has many simi-
larities to the WHO Policy on Collaborative Activities to 
reduce the dual burden of TB and HIV, and aims to 
guide policy makers and implementers on how to move 
forward and combat this looming dual epidemic. The 
response to the growing HIV-associated TB epidemic in 
the 1980s and 1990s was slow and uncoordinated, de-
spite clearly articulated warnings about the scale of the 
forthcoming problem. We must not make the same mis-
take with diabetes and TB. The Framework provides a 
template for action, and it is now up to donors, policy 
makers and implementers to apply the recommenda-
tions in the field and to ‘learn by doing’.
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Nothing will ever be attempted if all possible 
objections must fi  rst be overcome.
  — Samuel Johnson
WHEN the acquired immune-defi  ciency  syndrome 
(AIDS) was fi  rst reported in 1981, there was little re-
alisation at the time of the impending scale of the 
forthcoming epidemic or that the epicentre would be 
in sub-Saharan Africa. Thirty years on, the statistics 
make grim reading: 60 million infections, more than 
25 million deaths and more than 33 million persons 
currently living with human immunodefi  ciency virus 
(HIV) infection or AIDS.1 Sub-Saharan Africa has 
borne the brunt of this epidemic: the latest estimates 
are that 22.5 million persons are living with HIV/
AIDS, of whom an estimated 50% live in southern 
Africa.2 In 2009, about one third of all persons living 
with HIV (PLWH), one third of all new infections 
and one third of all AIDS-related deaths occurred in 
just 10 countries in southern Africa.2 
Chronic, non-communicable diseases such as 
c  ardiovascular disease, diabetes mellitus (DM), can-
cer and chronic obstructive pulmonary disease have 
insidiously emerged as the next twenty-fi  rst century 
global epidemic. These diseases have become the lead-
ing causes of death and disability worldwide, and are 
predicted to be the cause of over three quarters of 
global deaths by 2030.3 In parts of rural Africa, there 
is already an epidemiological transition, with chronic 
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care illness as a result of communicable (HIV/AIDS) 
and non-communicable diseases contributing more 
to mortality than acute care illness.4 The fact that 
chronic diseases are becoming increasingly important 
in the setting of economic development and a threat 
to health in low- and middle-income countries has 
been recognised by the United Nations General As-
sembly, and a high-level meeting with the participa-
tion of heads of state is to be hosted on the topic in 
September 2011.5 
Tuberculosis (TB) emerged early in the HIV epi-
demic as one of the most important and serious op-
portunistic infections to be associated with HIV, and 
has become the leading cause of death in HIV-infected 
persons.6 Nowhere is this more starkly apparent than 
in sub-Saharan Africa, where HIV has been responsi-
ble for an unprecedented increase in TB case notifi  ca-
tions and for derailing TB control efforts.7 In this ar-
ticle, we argue that there is an important interaction 
between DM and TB, the effects of which may be 
similar to those observed between HIV and TB. Al-
though at the individual level the risk of developing 
TB is considerably lower in persons with DM than in 
HIV patients, the much larger, and rapidly growing, 
pool of DM patients makes the global and popula-
tion attributable fraction of TB due to DM very simi-
lar to that seen with HIV.8 
We believe that DM-associated TB is the next loom-
ing challenge for global TB control, with the battle-
ground being focused in Asia, and particularly India 
and China. We compare and contrast the interactions, 
interventions and framework for collaborative activi-
ties between HIV and TB and DM and TB, and be-
lieve that if we are forewarned and prepared we stand 
a better chance of reducing the dual burden of disease 
of DM and TB than was the case with HIV and TB. 
THE DIABETES EPIDEMIC
According to a global analysis involving 199 countries 
and 2.7 million persons, the number of adults with 
DM increased alarmingly from 153 million in 1980 
to 347 million in 2008.9 Numbers are predicted to 
rise to 472 million by 2030, with almost 80% of DM 
patients living in low- and middle-income countries.10 
Although much of this increase in DM is attributed 
to population growth and aging, it also refl  ects a 
global shift towards a western lifestyle of unhealthy 
eating and physical inactivity. 
Although this is a global epidemic, Asia is the epi-
centre of the escalating burden of disease.9,11 Esti-
mates based on population growth, aging and urban-
isation indicate that India and China are, and will be, 
the two countries with the highest numbers of DM 
patients: the 199-country analysis estimated that 40% 
of DM patients (138 million in 2008) live in China 
and India. Among the next top eight countries, four 
more are in Asia: Indonesia, Pakistan, Bangladesh and 
the Philippines.11 As with HIV/AIDS in the early years, 
the scale of the epidemic is probably underestimated. 
A national representative survey in China involving 
over 46 000 adults between 2007 and 2008 showed, 
when extrapolated to the total population, that an 
estimated 92 million adults had DM, in contrast to a 
previous estimation of approximately 42 million.12 
Of note, and similar to the global situation with HIV, 
is the observation that in over 60% of adults with 
DM in China, the disease was undiagnosed at the time 
of the survey.12 
Morbidity and mortality accompany this rise in 
case burden. A hospital-based study in China, for ex-
ample, showed that more than half of persons with 
known DM experience chronic complications and ex-
hibit poor glucose control.13 In 2010, there were an 
estimated 3.5 million deaths due to DM worldwide.14 
EPIDEMIOLOGICAL INTERACTIONS 
BETWEEN HIV, DM AND TB
From the mid-1980s, TB programmes in countries 
with high HIV prevalence rates, particularly in sub-
Saharan Africa, saw rising TB case notifi  cations, and 
over a period of 10–15 years these increased up to 
500% in some countries. A number of recent litera-
ture reviews, which have included systematic reviews 
and meta-analyses of previous studies, have shown 
that DM patients have a signifi  cantly increased risk 
of developing active TB, which is two to three times 
higher than in persons without DM.15–18 Previous 
studies have tended to be secondary analyses of usu-
ally health facility-based data, and are subject to con-
founding and other limitations. Nevertheless, there 
has been a consistency in the fi  ndings, and prospec-
tive studies are currently underway. On the Texas-
Mexico border, for example, it was shown prospec-
tively that DM contributed 25% of TB cases, whereas 
HIV infection contributed ⩽5%.19 To date, little in-
formation has been published on whether DM has 
any effect on TB case notifi  cations or estimated case 
numbers at country level. However, an ecological as-
sociation between changes in DM and TB prevalence 
has been observed across 46 countries.20 Further-
more, an analysis of nutrition and DM changes in 
I  ndia suggests that increased DM prevalence between 
1998 and 2008 contributed to an increase in the total 
number of TB cases, which exceeded the rate of pop-
ulation growth in the same time period.21 It will be 
important to further focus on and monitor this asso-
ciation, especially in countries in Asia with escalating 
DM epidemics. 
MECHANISMS OF ASSOCIATION 
BETWEEN HIV, DM AND TB 
HIV causes disease by destroying cells of the immune 
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naive and memory CD4+ T-lymphocyte populations 
(which control the body’s defences against infection) 
being the hallmark of infection.22 The association be-
tween HIV and TB stems from two distinct processes: 
HIV increases the risk of reactivation in those who 
already have latent TB infection by up to 100 times; 
in those who acquire new TB infection, HIV increases 
the risk of progression to active disease.7 While the 
risk of active TB in an individual is related to the pre-
vailing socio-economic conditions and pressure of 
exogenous TB infection in the community, the critical 
determinant is the degree of immunodefi  ciency,  as 
measured by the CD4-lymphocyte count, with the 
lower counts and the amount of time accrued at low 
counts being signifi  cantly associated with increasing 
risk of TB.23 
DM increases the general risk of infection, but 
the precise mechanisms by which DM predisposes to 
TB are still not clear. DM does not reduce CD4+ T-
lymphocyte populations, but rather impairs the func-
tion and activation of macrophages, monocytes and 
lymphocytes which play a pivotal role in combating 
the TB pathogen.15,17,24,25 The relative contribution of 
other factors such as pulmonary microangiopathy, 
renal dysfunction and vitamin defi  ciencies remains to 
be established.15 DM patients with poorer glycaemic 
control appear to be at higher risk for TB,26,27 dem-
onstrating a dose-response relationship between the 
degree and duration of hyperglycaemia and vulnera-
bility to TB, rather similar to that observed with HIV 
and TB. 
EFFECT ON CLINICAL MANIFESTATIONS 
OF TB BY HIV AND DM
In PLWH, the clinical pattern of TB correlates with 
the host immune status. As the immune system be-
comes more compromised, granuloma formation de-
creases and the pattern of TB shifts from typical spu-
tum smear-positive, cavitary, upper-lobe pulmonary 
disease to atypical smear-negative, infi  ltrative, lower-
lobe pulmonary disease or extra-pulmonary dissemi-
nated disease. As CD4-counts decline to levels below 
100 cells/μl, the proportions of PLWH with culture-
confi  rmed pulmonary TB who have negative sputum 
smears, who are without radiographic cavities and 
who have normal chest radiographs, increase.28 
A similar, although not always consistent, picture 
may be found in DM patients.17 Nearly 90 years ago, 
it was reported that a large proportion of DM patients 
had lower lung involvement, in contrast to non-DM 
patients, who usually had upper lobe infi  ltrates.29 
While the predominance of lower-lobe infi  ltrates in 
DM patients has been confi  rmed in more recent stud-
ies,30,31 these fi  ndings are not consistent,17,32 and higher 
quality, prospective research in this area is needed. As 
is the case with HIV, it is likely that clinical and ra-
diographic manifestations of TB are a feature of host 
immune status, and poorly controlled DM patients 
with hyperglycaemia may have a higher frequency of 
atypical features of TB. 
ANTI-TUBERCULOSIS TREATMENT 
AND EFFECT ON TREATMENT OUTCOMES 
BY HIV AND DM 
International guidelines disseminated by the World 
Health Organization (WHO) recommend that treat-
ment for TB be standardised with 6-month rifampicin 
(RMP) based regimens.33 TB patients who are HIV-
infected should receive anti-tuberculosis treatment 
of the same duration as HIV-negative TB patients.33 
However, in industrialised countries, the optimal dura-
tion of treatment for HIV-infected TB patients is still 
controversial. For example, in the United States it is 
recommended that 6-month regimens be given, but 
this should be extended by 3 months if the patient pres-
ents with cavitary lung disease or is still sputum cul-
ture positive for Mycobacterium tuberculosis 2 months 
after the start of treatment.34 In DM patients, the 
same recommendations for a standardised 6-month 
anti-tuberculosis regimen apply, although clinicians 
in industrialised countries may take a more individu-
alised approach and consider the possibility of longer 
treatment as a result of the associated immune dys-
function.35 Whether longer treatment in TB patients 
with DM has a benefi  cial effect on treatment out-
comes and in reducing the risk of recurrent disease is 
not known and needs prospective research.36 
PLWH respond as well to anti-tuberculosis treat-
ment as non-HIV-infected patients, with similar rates 
of sputum conversion and radiographic improve-
ment. However, there are two major problems: in the 
absence of cotrimoxazole adjunctive therapy or anti-
retroviral therapy (ART), TB case-fatality rates are 
high, and are related, in sub-Saharan Africa at least, to 
the degree of HIV-related immune suppression.37 If a 
patient completes treatment satisfactorily, the rates of 
recurrent TB are much higher in HIV-infected than in 
HIV-negative patients.38,39 Low initial CD4 counts are 
a risk factor for recurrence,39 with most second epi-
sodes of TB being a result of re-infection with a new 
strain of M. tuberculosis.40 Standard anti-tuberculosis 
treatment on its own is not enough to reduce TB case 
fatality or recurrence.41 Interventions for both of these 
adverse events require timely initiation of cotrimox-
azole preventive therapy, ART and consideration of 
secondary isoniazid (INH) prophylaxis.42 
DM appears to have a similar effect on treatment 
outcomes (Table 1). A systematic review of studies, 
papers and reports from 1980 to December 2010 as-
sessed the results of sputum culture conversion at 2–
3 months of anti-tuberculosis treatment, death during 
treatment and relapse of TB after successful comple-
tion of treatment.43 Nine studies analysed culture posi-
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relative risks of >2, and three reporting relative risks 
of <1.43 However, all but one of the studies reported 
a delay in sputum culture conversion at some point 
during the course of anti-tuberculosis treatment. A 
total of 23 studies assessed risk of death during TB 
treatment, with a pooled and signifi  cantly higher rel-
ative risk of 1.89 in DM patients.43 Four of these stud-
ies adjusted for age and other potential confounders, 
fi  nding a pooled odds ratio of 4.95; this suggests that 
patients who die during anti-tuberculosis treatment 
have other strong risk factors for death, such as HIV 
and comorbidities, which reduce the impact of DM in 
unadjusted analyses. Five studies assessed the risk of 
TB relapse, with a pooled and increased signifi  cant 
relative risk of 3.89 in DM patients.43 Whether these 
patients experienced a recurrence of the former infec-
tion (true relapse) or re-infection with a new strain of 
M. tuberculosis is not known. 
There are many unanswered questions, including 
the infl  uence of poor DM control on death and recur-
rent TB, the timing and aetiology of death in DM pa-
tients, the reasons for recurrent disease, and interven-
tions that may reduce the frequency of these adverse 
events. These questions are best answered through 
prospective rather than retrospective studies. DM im-
pairs innate and adaptive immune responses, and poor 
DM control, as measured by glycosylated haemo-
globin (HbA1c) levels, affects in vitro innate and cell-
mediated immune cytokine responses.44 TB disease 
per se and the drugs used to treat TB, such as RMP, 
can all worsen DM control, particularly the use of 
RMP as a result of direct and indirect interactions 
with oral hypoglycaemic drugs.45 Uncontrolled DM 
can eventually lead to impaired renal function and an 
increased risk of drug toxicities. Hepatic toxicity due 
to anti-tuberculosis drugs may also be increased in 
DM patients, potentially increasing the risk of ad-
verse treatment outcomes.46 
SCREENING TB PATIENTS FOR HIV AND DM 
AND REFERRAL TO CARE
The crucial fi  rst step for ensuring access to HIV pre-
vention and care in TB patients in high TB-HIV bur-
den countries is to ensure that they are counselled 
and tested for HIV. The WHO recommends that 
provider-initiated HIV testing and counselling (PITC) 
be offered as a routine service,47 and this has been 
shown to be both feasible and acceptable in various 
settings.48,49 Rates of HIV testing have increased dra-
matically in the last 5 years, probably as a conse-
quence of the advent of ART. In 2009, over 50% of 
TB patients in sub-Saharan Africa were tested for 
HIV.49 HIV testing establishes the diagnosis of HIV 
and serves as the gateway to HIV-related prevention 
and care interventions. 
While it is acknowledged that TB patients would 
merit being screened for DM,50 especially in high DM 
burden areas, how this is best done and carried out in 
routine settings is not known. Possible screening tests 
might include measurement of urine glucose, random 
blood glucose, fasting blood glucose, oral glucose tol-
erance testing and HbA1c. HbA1c has recently been 
endorsed by the WHO as a diagnostic test for DM,51 
although its sole use as a diagnostic test is still con-
troversial.52 Despite its obvious attraction, urine test-
ing for glucose is sub-optimal for early case fi  nding of 
DM at the primary health care level.53 
In high-burden countries, action is already being 
taken. In Kerala State, India, the Revised National TB 
Control Programme has already initiated screening 
of TB patients for DM and is assessing its effect on 
TB treatment outcomes under routine programme 
conditions (L S Chauhan, personal communication). 
A recent stakeholders’ meeting in China agreed that 
a feasible and potentially affordable working strat-
egy would be to screen TB patients at registration 
and start of anti-tuberculosis treatment by random 
blood glucose (RBG) tests; if RBG was >6.1 mmol/l, 
patients could be asked to return at the next visit 
for a fasting blood glucose (FBG) test; an FBG > 
7.0 mmol/l would indicate a diagnosis of DM54 and 
the need for referral to DM care for confi  rmation of 
diagnosis and optimal blood glucose management, 
particularly as blood glucose levels may be elevated 
in the setting of acute TB infection50 (A D Harries 
and L Yan, personal communication).
PREVENTING AND REDUCING THE BURDEN 
OF TB IN PLWH AND DM
In PLWH, early initiation of ART through immune 
reconstitution reduces the risk of TB,55 and this has 
led the WHO to recommend that ART should be ini-
tiated at CD4 count thresholds of 350 cells/μl rather 
than 200 cells/μl.56 Mathematical modelling using 
the case reproduction number, long-term dynamics of 
the HIV epidemic, data from South Africa and the 
known effects of HIV on TB incidence, suggests that 
a strategy of HIV testing and immediate start of ART 
could, in a short period of time, signifi  cantly reduce 
the incidence of HIV-associated TB;23 this approach 
needs to be evaluated and tested. Further reduction 
in the risk of TB could be achieved through imple-
mentation of the ‘Three I’s’: intensifi  ed case fi  nding, 
Table 1  Main adverse outcomes in HIV-infected patients and 
patients with diabetes who are being treated for TB
Adverse outcomes
Patients 
with HIV
Patents 
with diabetes
Case fatality during anti-tuberculosis 
treatment Increased Increased
Recurrence of TB after successful 
completion of anti-tuberculosis 
treatment Increased Increased
HIV = human immunodeﬁ  ciency virus; TB = tuberculosis.1440  The   International   Journal   of   Tuberculosis   and   Lung   Disease
infection control and INH preventive therapy (IPT).42 
Symptom screening for TB using cough of any dura-
tion, weight loss, night sweats and fever now has a 
sound evidence base for policy recommendations.57,58 
There are good guidelines on what to do and how to 
implement TB infection control in health care facili-
ties.59 The effi  cacy of IPT in reducing the risk of ac-
tive TB in PLWH with latent TB infection has been 
well established through clinical trials.60 Evidence 
has recently shown that 36 months of IPT is more ef-
fective than 6 months at reducing the risk of TB 
among PLWH.61 What remains now is implementa-
tion of policy recommendations in HIV care clinics in 
high HIV and TB burden countries. 
In a similar vein, good DM control should reduce 
the risk of TB, as evidenced by a higher risk of TB in 
people with poorly controlled DM compared to those 
with well controlled DM.26,27 Although no data are 
available from recent intervention studies to support 
the use of IPT, two observational studies conducted 
in Germany in the 1950s and Russia in the 1960s 
showed that chemoprophylaxis with either INH or 
an INH analogue respectively reduced the primary 
and secondary risk of TB in DM patients.62,63 How-
ever, the absence of randomisation and the lack of 
details of the interventions in these two studies limit 
the evidence base to support IPT in DM patients. 
While it is acknowledged that DM patients living in 
high TB burden countries might merit active screen-
ing for TB,50 experience in routine health settings 
about how to do this is limited. TB screening should 
be performed at each visit using a simple symptom 
screen similar to what has been adopted for intensi-
fi  ed case fi  nding in PLWH.58 Screening by chest X-ray 
could also be considered at the time of DM diagnosis, 
and possibly at regular intervals thereafter. If screen-
ing identifi  es a signifi  cant number of previously un-
diagnosed TB cases, the issue of infection control 
should not be forgotten, and guidelines to prevent 
nosocomial TB transmission within HIV care facili-
ties should be considered for DM clinics. The concept 
of the Three I’s for PLWH should be considered, 
adapted and evaluated in DM patients as a way of re-
ducing the dual disease burden.
MONITORING, RECORDING AND REPORTING
Effective collaboration between TB and HIV pro-
grammes demands that each reliably monitor and re-
port on one another’s parameters. This has been an 
iterative process, guided by intuition and experience, 
resulting in a revised international guide that spells 
out the data required for denominators, numerators 
and indicators to monitor progress in HIV care in TB 
patients and TB preventive efforts in PLWH.64 Treat-
ment cards, registers and cohort reporting forms have 
required modifi  cation and revision to accommodate 
such collaboration on the ground. 
At present little is known on how to conduct such 
monitoring in DM and TB, and operational research 
will be needed to test out different modalities. The re-
cent stakeholders’ meeting in China agreed on some 
ways forward (A D Harries and L Yan, personal com-
munication). A register similar to that shown in Fig-
ure 1 might be a useful tool to be used alongside the 
Patient TB Register to monitor DM screening in TB 
patients, with a template for the cohort reporting 
shown in Table 2. A treatment card similar to that 
shown in Figure 2 might be a useful tool to moni-
tor TB screening in DM patients when they attend 
the DM clinic, with a template for the cohort report-
ing shown in Table 3. These suggested tools need 
to be piloted and evaluated in fi  eld conditions in vari-
ous settings. 
FRAMEWORK FOR COLLABORATION
One of the important milestones in the fi  ght against 
HIV and TB was the publication and dissemination 
in 2004 of the WHO Interim Policy of Collaborative 
Figure 1  DM screening register for TB patients. Ten rows per page (therefore 10 patients per page). If RBG > 6.1 mmol/l (110 mg/dl), 
do second screen with FBG at next visit. If FBG > 7.0 mmol/l (126 mg/dl), diagnosis = DM and refer to diabetes care. TB = 
t  uberculosis; DM = diabetes mellitus; Y = yes; N = no; RBG = random blood glucose; FBG = fasting blood glucose.The   looming   diabetes-TB   epidemic  1441
HIV and TB Activities to reduce the joint burden of 
the two diseases (Table 4).65 As the evidence base for 
policy recommendations was weak at that time, the 
guidance was promoted as interim in nature. New 
evidence and experience has since become available, 
and as a result the policy has been updated and should 
be published in 2011. 
An important step in the fi  ght against DM and 
TB has been the development of a WHO-Union 
Framework for Collaborative activities to guide pol-
icy makers and implementers in reducing the dual 
burden of DM and TB (Table 5).66 This was developed 
through an iterative process,67 with the WHO giving 
clearance to develop a Framework rather than Guide-
lines due to lack of strong evidence to support some 
of the suggested interventions. The Framework was 
printed in August 2011,66 and will serve as a guide to 
help policy makers and implementers move forward 
to combat the looming epidemic. It will be important 
to ensure that interventions are delivered within the 
context of general health systems, that they take into 
account other chronic non-communicable diseases, 
and that engagement is sought both with and from 
civil society. 
CONCLUSION
The global and national response to the HIV-associ-
ated TB epidemic was slow and uncoordinated. The 
fi   rst reports of the association between HIV/AIDS 
and TB were published in the late 1980s,68,69 and 
warnings were clearly articulated in the early 1990s 
about the impending scale of the forthcoming dual 
Table 2  Quarterly report of diabetes screening 
in TB patients*
Number of TB patients registered
Number already known with DM
Number screened with RBG
Number with RBG > 6.1 mmol/l (110 mg/dl)
Number screened with FBG
Number with FBG < 6.1 mmol/l (110 mg/dl)
Number with FBG 6.1–7.0 mmol/l (110–126 mg/dl)
Number with FBG > 7.0 mmol/l (126 mg/dl)
Number newly diagnosed with DM (FBG > 7.0 or 126 mg/dl)
Number with known DM + number with new DM
Number referred to diabetes care
Number conﬁ  rmed with DM in diabetes clinic and entered to 
DM care 
* Quarterly report completed 1 month after end of the quarter.
TB = tuberculosis; DM = diabetes mellitus; RBG = random blood glucose; 
FBG = fasting blood glucose.
Table 3  Quarterly report of TB screening 
in diabetes patients* 
Number of DM patients ever registered up to end of the quarter
Number of DM patients seen in the clinic in the quarter
Number of DM patients screened for TB symptoms in quarter
  (screened at least once)
Number of DM patients with a positive TB symptom screen
Number of DM patients referred for TB investigations
Status of DM patients referred for TB investigations
  Number referred for TB investigations in quarter
  Number diagnosed with TB
  Number registered with TB
  Type of TB
  Smear-positive  PTB
  Smear-negative  PTB
  EPTB
  Category of TB
  New  or  recurrent 
  Number started on anti-tuberculosis treatment
* Quarterly report completed 1 month after end of the quarter.
TB = tuberculosis; DM = diabetes mellitus; PTB = pulmonary tuberculosis; 
EPTB = extra-pulmonary tuberculosis.
Figure 2  Diabetes treatment card and TB screening. DM = diabetes mellitus; TB = tuberculosis; Y = yes; N = no.1442  The   International   Journal   of   Tuberculosis   and   Lung   Disease
epidemic.70,71 Little action was taken, and HIV and 
TB programmes barely interacted at global, national 
or district levels. It was not until 2004, with the re-
lease of the WHO interim policy,42 that collaborative 
HIV and TB activities got under way and progress was 
made in the fi  ght against the two diseases. We cannot 
afford to make the same mistake with DM and TB.
In low- and middle-income countries, the DM epi-
demic is growing quickly. In sub-Saharan Africa, the 
absolute numbers of DM patients are predicted to 
grow from 12 million in 2010 to 24 million by 2030, 
with most cases undiagnosed and untreated.72 How-
ever, it is Asia, as we have said earlier, that will bear 
the brunt of this epidemic, with the number of DM 
patients in South-East Asia and the Western Pacifi  c 
predicted to reach over 210 million by 2030.14 Epide-
miological models using 2000 data in India have al-
ready shown the important interaction between DM 
and TB in that country, with DM accounting for 20% 
of smear-positive pulmonary TB cases,73 and recent 
analyses have indicated that the increase in DM prev-
alence in India has been a signifi  cant impediment to 
reducing TB incidence in that country.21 
We must learn from the TB-HIV epidemic. One 
of the important keys to controlling the TB-HIV epi-
demic lies in preventing new HIV infections, and a 
milestone in this regard has been the recent recogni-
tion of the important TB preventive role of ART.42 
With a global DM epidemic that is escalating rap-
idly, the prevention and control of DM is likely to be 
an equally important intervention in controlling the 
DM-TB epidemic. Primary prevention of DM through 
attention to unhealthy diets, sedentary lifestyles and 
childhood and adult obesity must be included in 
broad prevention strategies for non-communicable 
diseases. Better integration of communicable and non-
communicable disease prevention and care strategies 
that are focused on the patient rather than the disease 
is required. As with TB-HIV, we must adapt and apply 
similar methods of preventing, screening and treating 
the two diseases together, and ensure that we have se-
cure pipelines for drugs, that we develop mechanisms 
of working together, that we undertake relevant op-
erational and other kinds of research,36 and that we 
adopt the philosophy of ‘learning by doing’. We may 
then stand a good chance of winning this war. 
Disclaimer
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La prévalence du diabète sucré augmente à un rythme 
dramatique et des pays d’Asie, particulièrement l’Inde et 
la Chine, porteront le choc de cette épidémie. Chez les 
sujets atteints de diabète, le risque de la tuberculose 
(TB) active est significativement augmenté et de deux à 
trois fois supérieur à celui des personnes sans diabète. 
Dans cet article, nous soutenons que les interactions épi-
démiologiques et les effets de l’interaction entre le dia-
bète et la TB sur sa présentation clinique et le traite-
ment résultant sont similaires à ceux observés en matière 
de VIH et de TB. Les leçons retenues des approches 
visant à réduire le fardeau double du VIH et de la TB, et 
particulièrement les modes de dépistage des deux mala-
dies, peuvent être adaptées et appliquées au dépistage, au 
diagnostic, au traitement et à la prévention du diabète 
associée à la TB. Le nouveau Réseau de Collaboration 
de l’OMS et L’Union pour les soins et la maîtrise de la 
TB et du diabète est similaire à beaucoup d’égards à la 
politique de l’OMS sur les activités de collaboration 
visant à réduire le double fardeau de la TB et du VIH ; il 
vise à orienter les concepteurs de politique et ceux qui 
l’appli  quent sur la façon de progresser et de combattre 
cette double épidémie en extension. La réponse à l’épidé-
mie progressive de TB associée au VIH dans les années 
1980 et 1990 a été lente et mal coordonnée en dépit des 
avertissements clairement articulés concernant l’étendue 
du problème à venir. Nous ne devons pas commettre la 
même erreur en ce qui concerne le diabète et la TB. Ce 
réseau fournit un gabarit pour l’action ; c’est maintenant 
aux donateurs, aux concepteurs de politique et à ceux 
qui la mettent en œuvre qu’il revient d’appliquer les re-
commandations dans ce domaine ainsi que de «    se for-
mer par l’action  ». 
La prevalencia de diabetes sacarina aumenta a un ritmo 
alarmante y algunos países de Asia, en especial la India 
y China, soportarán la mayor carga de esta epidemia. 
Las personas diabéticas presentan un riesgo de padecer 
tuberculosis (TB) activa que es dos a tres veces más alto 
que el riesgo de las personas sin diabetes. En el presente 
artículo se propone que las interacciones epidemioló-
gicas y clínicas con respecto al modo de presentación y 
al tratamiento son equivalentes a las interacciones que 
se han observado en la coinfección por el virus de la 
i  nmunodeficiencia humana (VIH) y la TB. Las lecciones 
extraídas de las estrategias encaminadas a disminuir la 
carga de morbilidad por esas dos enfermedades, sobre 
todo en materia de métodos de detección sistemática, se 
pueden aplicar a la detección, el diagnóstico, el trata-
miento y la prevención de la diabetes y la TB. El nuevo 
marco de acción conjunta para la atención y el control 
de la TB y la diabetes de La Unión y la Organización 
Mundial de la Salud (OMS) muestra muchas similitudes 
con la política de la OMS sobre las actividades de colabo-
ración que tienden a aliviar la carga de morbilidad por 
TB e infección por el VIH; el marco tiene como objetivo 
guiar a las instancias normativas y ejecutoras en el pro-
greso de la lucha contra esta inminente epidemia doble. 
En los años 1980 y 1990, la respuesta a la epidemia 
progresiva de coinfección por el VIH y la TB fue lenta 
y des  coordinada, pese a las alertas que se expresaron 
claramente sobre la amplitud del problema que se acer-
caba. No se debe cometer el mismo error con la diabetes 
y la TB. Este marco ofrece un modelo para la acción y es 
ahora responsabilidad de los donantes y las instancias 
normativas y ejecutoras que se apliquen las recomenda-
ciones en el terreno y ‘se aprenda actuando’.
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RESUMEN